Sloan-Kettering Institute for Cancer Research

Columbia University

Yale University

Other

Nereus Pharmaceuticals, Inc.

General Electric Company

Cornell University

Duke University

Dana-Farber-Cancer Institute Inc.

The Scripps Research Institute

Memorial Sloan Kettering Cancer Center

Samuel J Danishefsky

Ting-Chao Chou

Philip O Livingston

Kenneth Allen Savin

Peter Bertinato

Dai-Shi Su

Erik J Sorensen

Ted Kamenecka

Aaron Balog

Govindaswami Ragupathi

Scott D Kuduk

Dang Fang Meng

William G Bornmann

Ana E Gabarda

Huajin Dong

Alexey Rivkin

Lawrence Williams

Neal Rosen

Christoph Gaul

Dongfang Meng

Joseph R Bertino

Dalibor Sames

Laura Sepp-Lorenzino

Jennifer Rebecca Allen

Malcolm A S Moore

In Jong Kim

David C Dorn

Peter W Glunz

Kenneth O Lloyd

Ouathek Ouerfelli

Thomas V Magee

Jon T Njardarson

Mihirbaran Mandal

Samuel Hintermann

Wang Shen

Yoshimura Fumikiko

Randall L Halcomb

DongFang Meng

Kaida Wu

Yves Queneau

Mark D Wittman

Tae Kyo Park

John T Randolph

Walter J Krol

Christina Harris

Xiu-Guo Zhang

Bishan Zhou

Shawn J Stachel

Taeyoung Yoon

Xiao-Tao Chen

Joan Massague

Vadim Y Dudkin

Govind Ragupathi

J David Warren

Taotao Ling

Guangli Yang

Jón T Njardarson

Jianglong Zhu

Fumihiko Yoshimura

Stacy J Keding

Manuel Valiente Cortes

Thordur Oskarsson

Fumikiko Yoshimura

Nicolas Lecomte

Furzhong F Zheng

Ouatek Ouerfelli

Lawrence B Snyder

Craig A Coburn

Matthew D Shair

Shuang Hua Hu

Larry Neil Lewis

Richard A Lerner

Barton F Haynes

David A Scheinberg

Steven R Magnuson

Bin Wu

Hua-Xin Liao

Kim D Janda

Joseph G Sodroski

Jacques Y Roberge

Robert M Garbaccio

Chris A Sumpter

Xin-Yun Huang

Daniel Baeschlin

Malcolm A Moore

Richard C Isaacs

Zihao Hua

Howard Scher

David Spriggs

Mark Donald Chappell

Heedong Yun

Christophe Antczak

Barry D Kahan

John Hartung

Krishnakumar Ranganathan

Xiao Tao Chen

Peter Kinam Park

Fay Ng

David Solit

Jacob Bradely Schwarz

The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a vaccine for HIV-1, comprising synthetic V3 glycopeptides, and to methods of making and using same.

Cyclic HIV-1 Env V3 glycopeptide immunogens

Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated.

Glycopeptide constructs and uses thereof

This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Le, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.

Polyvalent conjugate vaccine for cancer

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Migrastatins and uses thereof

Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.

Multivalent glycopeptide constructs and uses thereof

The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein.

Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof

In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis. 

Migrastatin analogs in the treatment of cancer

The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I). 

Compounds, compositions and methods for reducing toxicity and treating or preventing diseases

The present invention provides compounds having formula (I): 

Migrastatin analogs and uses thereof

The present invention provides isolated homogeneous polyfunctionalized proteins (e.g., erythropoietin), isolated glycopeptides, and a method for preparing polyfunctionalized peptides and/or proteins via cysteine-free native chemical ligation. In certain embodiments, the invention provides an isolated homogeneous polyfunctionalized protein having the structure (I). In certain other embodiments, the invention provides an isolated glycopeptide having Formula (II). In certain other embodiments, the inventive method is a method for preparing a polyfunctionalized peptide comprising a peptidic backbone made up of four or more amino acids, wherein two or more non-adjacent amino acids are independently substituted with a moiety having the structure (III) -LH. wherein A and L1 are as defined herein.

Compositions comprising homogeneously glycosylated erythropoietin

The present invention provides compounds of formula (I): 

Synthesis of epothilones, intermediates thereto and analogues thereof

Growing community of inventors

Englewood, NJ, United States of America

Samuel J Danishefsky